Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 57 articles:
HTML format



Single Articles


    October 2025
  1. BURDET C, Saidani N, Dupieux C, Lemaignen A, et al
    Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01624-1. doi: 10.1016/S0140-6736(25)01624.
    PubMed     Abstract available


  2. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    PubMed     Abstract available


    September 2025
  3. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    PubMed     Abstract available


    August 2025
  4. DROBNIEWSKI F, Kon OM, Gonzalo X, Ashmi M, et al
    Why are we failing to rapidly diagnose tuberculosis in the UK?
    Lancet. 2025;406:908-909.
    PubMed    


    July 2025
  5. ABUZERR S, Hamdan H, Charafeddine J
    Paediatric meningitis outbreak in Gaza amid health system collapse.
    Lancet. 2025 Jul 31:S0140-6736(25)01520-X. doi: 10.1016/S0140-6736(25)01520.
    PubMed    


  6. MACIEL EL, Pablos-Mendez A, Abubakar I
    Undoing progress through sudden tuberculosis funding cuts.
    Lancet. 2025 Jul 3:S0140-6736(25)01328-5. doi: 10.1016/S0140-6736(25)01328.
    PubMed    


  7. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    PubMed     Abstract available


    June 2025
  8. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    PubMed     Abstract available


  9. AL ZAMEL AM, Saeed AA, Elmubarak M, Alsarraj MA, et al
    Sudan's tuberculosis response needs global support amid conflict.
    Lancet. 2025 Jun 2:S0140-6736(25)01119-5. doi: 10.1016/S0140-6736(25)01119.
    PubMed    


    May 2025
  10. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    PubMed     Abstract available


  11. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
    Gastric cancer.
    Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
    PubMed     Abstract available


    April 2025
  12. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    PubMed     Abstract available


  13. KLUGE HHP
    Tuberculosis: a threat to health security in the European region and the collective actions needed.
    Lancet. 2025 Apr 7:S0140-6736(25)00677-4. doi: 10.1016/S0140-6736(25)00677.
    PubMed    


    March 2025
  14. DHEDA K, Perumal T, Fox GJ
    Asymptomatic tuberculosis: undetected and underestimated, but not unimportant.
    Lancet. 2025 Mar 21:S0140-6736(25)00555-0. doi: 10.1016/S0140-6736(25)00555.
    PubMed    


  15. JERENE D, van Kalmthout K, Levy J, Alacapa J, et al
    Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
    Lancet. 2025 Mar 11:S0140-6736(24)02847-2. doi: 10.1016/S0140-6736(24)02847.
    PubMed     Abstract available


  16. MARX FM, Civan A
    Rethinking the benefits of digital adherence technologies for tuberculosis treatment.
    Lancet. 2025 Mar 11:S0140-6736(25)00199-0. doi: 10.1016/S0140-6736(25)00199.
    PubMed    


  17. TROTTER C, Diallo K
    Another step towards defeating meningitis.
    Lancet. 2025 Mar 11:S0140-6736(25)00196-5. doi: 10.1016/S0140-6736(25)00196.
    PubMed    


  18. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    PubMed     Abstract available


  19. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    PubMed     Abstract available


    February 2025
  20. ZUMLA A, Sahu S, Yeboah-Manu D, Goletti D, et al
    Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts.
    Lancet. 2025 Feb 26:S0140-6736(25)00335-6. doi: 10.1016/S0140-6736(25)00335.
    PubMed    


  21. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    PubMed     Abstract available


    January 2025
  22. MACESIC N, Uhlemann AC, Peleg AY
    Multidrug-resistant Gram-negative bacterial infections.
    Lancet. 2025;405:257-272.
    PubMed     Abstract available


    October 2024
  23. BHARGAVA A, Bhargava M, Velayutham B, Benedetti A, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial - Authors' reply.
    Lancet. 2024;404:1524.
    PubMed    


  24. ZHANG K, Xu Y, Hu Y, Chen X, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1523-1524.
    PubMed    


  25. BUSANG J, Khan P
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522-1523.
    PubMed    


  26. RICKMAN HM, Yates TA
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522.
    PubMed    


  27. KAUR JABINDA M
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1521-1522.
    PubMed    


  28. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    PubMed     Abstract available


  29. BHATTARAI MD
    Utilising available isoniazid-resistance tests in new patients.
    Lancet. 2024;404:1403.
    PubMed    


  30. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    PubMed    


    September 2024
  31. KHAN M
    "The final warning sign": XDR typhoid.
    Lancet. 2024;404:1182-1183.
    PubMed    


  32. VAN RHIJN N, Arikan-Akdagli S, Beardsley J, Bongomin F, et al
    Beyond bacteria: the growing threat of antifungal resistance.
    Lancet. 2024;404:1017-1018.
    PubMed    



  33. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    PubMed     Abstract available


  34. HIRATE T, Kanda K, Ohshima Y, Shinoda K, et al
    Congenital syphilis in a 2-month-old infant during Japanese outbreak.
    Lancet. 2024;404:971.
    PubMed    


    August 2024
  35. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    PubMed    


  36. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    PubMed    


    July 2024
  37. LI M, Kim JB, Sastry BKS, Chen M, et al
    Infective endocarditis.
    Lancet. 2024;404:377-392.
    PubMed     Abstract available


    June 2024
  38. HYDE L
    Mobile screening for Ukraine's wartime tuberculosis epidemic.
    Lancet. 2024;403:2771.
    PubMed    


  39. MCCANN N, Vicentine MP, Pollard AJ
    Towards paratyphoid control: the vital role of the challenge model.
    Lancet. 2024;403:2780-2781.
    PubMed    


  40. CRENNER C
    Ulcers, stress, and the discovery of Helicobacter pylori.
    Lancet. 2024;403:2586-2587.
    PubMed    


  41. WHITE NJ
    Death from diphtheria.
    Lancet. 2024;403:2590-2591.
    PubMed    


  42. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    PubMed    


  43. ALMADI MA, Lu Y, Alali AA, Barkun AN, et al
    Peptic ulcer disease.
    Lancet. 2024 Jun 14:S0140-6736(24)00155-7. doi: 10.1016/S0140-6736(24)00155.
    PubMed     Abstract available


  44. MARIONI G, Franz L, Incognito A, Bitonti S, et al
    Bilateral simultaneous cochlear implant in an adult with anacusis due to bacterial meningitis.
    Lancet. 2024;403:2533.
    PubMed    


  45. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    PubMed    


  46. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    PubMed    


    May 2024
  47. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed     Abstract available


  48. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    PubMed     Abstract available


  49. OKEKE IN, de Kraker MEA, Van Boeckel TP, Kumar CK, et al
    The scope of the antimicrobial resistance challenge.
    Lancet. 2024 May 20:S0140-6736(24)00876-6. doi: 10.1016/S0140-6736(24)00876.
    PubMed     Abstract available


  50. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed     Abstract available


  51. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    


    March 2024
  52. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    PubMed    


  53. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed     Abstract available


  54. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    PubMed    


  55. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    PubMed    


  56. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    PubMed    


  57. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.